Clinical Trials Logo

Pleural Mesothelioma clinical trials

View clinical trials related to Pleural Mesothelioma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05077111 Active, not recruiting - Clinical trials for Pulmonary Atelectasis

A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia

VATS
Start date: January 15, 2020
Phase: Phase 4
Study type: Interventional

Video-assisted thoracic surgery (VATS) is usually performed with general anesthesia and single lung ventilation. However, performing thoracic surgery under awake regional anesthesia has several potential advantages including avoidance of airway trauma and ventilator dependence associated with endotracheal intubation, besides promoting enhanced recovery after surgery and shorter mean hospital stay.

NCT ID: NCT04914897 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Start date: September 23, 2021
Phase: Phase 2
Study type: Interventional

Primary Objective: -To determine the antitumor activity of SAR444245 in combination with other anticancer therapies. Secondary Objectives: - To confirm the dose and to assess the safety profile of SAR444245 when combined with other anticancer therapies. - To assess other indicators of antitumor activity. - To assess the pharmacokinetic (PK) profile of SAR444245 when given in combination with pembrolizumab. - To assess the immunogenicity of SAR444245.

NCT ID: NCT04334759 Active, not recruiting - Mesothelioma Clinical Trials

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

DREAM3R
Start date: February 18, 2021
Phase: Phase 3
Study type: Interventional

Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the study doctor, which is either standard chemotherapy or immunotherapy combination (ipilimumab and nivolumab). Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the body's immune system attack cancer cells. Research has shown that durvalumab can slow tumor growth and shrink tumors in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with PM.

NCT ID: NCT04040231 Active, not recruiting - Mesothelioma Clinical Trials

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Start date: July 24, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test whether it is safe to give Galinpepimut-S and Nivolumab together in patients with mesothelioma.